Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853996 · ClinicalTrials.gov registry record · Phase 2
Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00853996 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 25 participants.
The verdict
NCT00853996, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial is studying how well acolbifene works in preventing cancer in premenopausal women at high risk of breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acolbifene may stop cancer from growing or coming back.
Interventions
- DRUG acolbifene hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853996
The ClinicalTrials.gov registry entry for NCT00853996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which acolbifene hydrochloride is the first listed.
NCT00853996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853996 about?
NCT00853996 is a clinical study titled "Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer". This phase II trial is studying how well acolbifene works in preventing cancer in premenopausal women at high risk of breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acolbifene may stop cancer from growing or coming back.
What is the current status of trial NCT00853996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-02. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00853996?
The interventions under investigation include: acolbifene hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00853996?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.